SCHEMBL3885170

SCHEMBL3885170

CC(Oc1ccc(Oc2ccc3ccc(Cl)cc3n2)cc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
MAPT P10636 2/20 0.57
TP53 P04637 1/20 0.57
CYP3A4 P08684 1/20 0.57
ALOX15 P16050 1/20 0.57
NFKB1 P19838 1/20 0.57
HIF1A Q16665 1/20 0.57
GMNN O75496 1/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
HPGD P15428 1/20 0.57
APEX1 P27695 1/20 0.57
PMP22 Q01453 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TSHR P16473 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
MAP4K4 O95819 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3573474 1.00 CYP1A2 (0.57) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL3887207 1.00 CYP1A2 (0.57) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL3893051 0.99 CYP1A2 (0.56) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL27259282 0.91 CYP1A2 (0.56) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL9587966 0.91 CYP1A2 (0.56) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL3893049 0.88 MAPT (0.74) CYP1A2MAPTTP53CYP3A4ALOX15
Hydrochloric Acid SCHEMBL10946610 0.86 MAPT (0.46) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL3886045 0.86 AKR1C3 (0.47) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL13316457 0.86 TDP1 (0.48) CYP1A2MAPTTP53CYP3A4ALOX15
SCHEMBL27259406 0.86 TDP1 (0.48) CYP1A2MAPTTP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241894-B2 Antitumor agents WAYNE STATE UNIVERSITY (US) 2007-07-10 US claimed
US-6867219-B2 Antitumor agents WAYNE STATE UNIVERSITY (US) 2005-03-15 US claimed
EP-1412332-B1 QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS UNIV WAYNE STATE (US) 2005-01-19 EP claimed
EP-1412332-A1 QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS WAYNE STATE UNIVERSITY (US) 2004-04-28 EP claimed
US-20030144321-A1 Antitumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-31 US claimed
WO-2003011832-A1 QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS WAYNE STATE UNIVERSITY (US) 2003-02-13 WO claimed
US-7507749-B2 Antitumor agents WAYNE STATE UNIVERSITY (US) 2009-03-24 US disclosed
US-20070232643-A1 Quinoline derivative, e.g. 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt; anticarcinogenic, antitumor agent; colon, breast, melanoma, pancreatic cancer or adenocarcinoma; melanoma, or leukemia; based on herbicides WAYNE STATE UNIVERSITY 2007-10-04 US disclosed
US-7241894-B2 Antitumor agents WAYNE STATE UNIVERSITY (US) 2007-07-10 US disclosed
US-20050159447-A1 Antitumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-07-21 US disclosed
US-6867219-B2 Antitumor agents WAYNE STATE UNIVERSITY (US) 2005-03-15 US disclosed
EP-1412332-B1 QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS UNIV WAYNE STATE (US) 2005-01-19 EP disclosed
EP-1412332-A1 QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS WAYNE STATE UNIVERSITY (US) 2004-04-28 EP disclosed
WO-2004004651-A2 THERAPEUTIC AMIDES WAYNE STATE UNIVERSITY (US) 2004-01-15 WO disclosed
US-20030144321-A1 Antitumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-31 US disclosed
WO-2003011832-A1 QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS WAYNE STATE UNIVERSITY (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232643-A1 Quinoline derivative, e.g. 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt; anticarcinogenic, antitumor agent; colon, breast, melanoma, pancreatic cancer or adenocarcinoma; melanoma, or leukemia; based on herbicides NRAS, KRAS, BRAF CYP1A2 1414/4885MAPT 4155/4885TP53 18/4885
US-20030144321-A1 Antitumor agents MCL1, FLI1, MGMT CYP1A2 3119/4885MAPT 4778/4885TP53 5/4885
US-20050159447-A1 Antitumor agents MGMT, TP53, MCL1 CYP1A2 3146/4885MAPT 4797/4885TP53 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.